Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Chiche E, Rahmé R, Bertoli S, Dumas PY, Micol JB, Hicheri Y, Pasquier F, Peterlin P, Chevallier P, Thomas X, Loschi M, Genthon A, Legrand O, Mohty M, Raffoux E, Auberger P, Caulier A, Joris M, Bonmati C, Roth-Guepin G, Lejeune C, Pigneux A, Vey N, Recher C, Ades L, Cluzeau T.
Chiche E, et al. Among authors: lejeune c.
Blood Adv. 2021 Jan 12;5(1):176-184. doi: 10.1182/bloodadvances.2020003159.
Blood Adv. 2021.
PMID: 33570629
Free PMC article.